非小细胞肺癌的分子靶向治疗

doi:10.3760/cma.j.issn.1673-422X.2018.01.009

摘要/Abstract

摘要： 目前非小细胞肺癌（NSCLC）的治疗已经进入靶向治疗时代，小分子酪氨酸激酶抑制剂为典型代表，它们有明确的分子靶标并且疗效显著，但许多基因未突变的患者不能从中获益。血管内皮生长因子及免疫靶向治疗成为NSCLC治疗的新焦点，程序性死亡受体1与其配体等抑制剂在一系列NSCLC临床试验中显示出了巨大的应用潜力。

关键词: 癌, 非小细胞肺；免疫毒素类；治疗应用

Abstract: At present, the treatment of nonsmall cell lung cancer (NSCLC) has entered the era of targeted therapy, and small molecule tyrosine kinase inhibitors are typical representatives, which have clear molecular targets and remarkable effects. But many patients without mutations are not able to benefit from them. Vascular endothelial growth factor and immune targeted therapy have become the new focus of NSCLC treatment. Inhibitors such as programmed cell death1 and programmed cell deathligand 1 have shown great applied potential in a series of clinical trials of NSCLC.

Key words: Carcinoma, nonsmallcell lung, Immunotoxins, Therapeutic uses

南兆棣，陈绍水. 非小细胞肺癌的分子靶向治疗[J]. 国际肿瘤学杂志, 2018, 45(1): 39-.

Nan Zhaodi, Chen Shaoshui. Molecular targeted therapy of nonsmall cell lung cancer[J]. Journal of International Oncology, 2018, 45(1): 39-.

参考文献

［1］ Ma W, Xu M, Liu Y, et al. Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced nonsmallcell lung cancer: a metaanalysis of fifteen phase Ⅱ/Ⅲ randomized trials［J］. Int J Cancer, 2015, 137(2): 409419. DOI: 10.1002/ijc.29377. ［2］ Minguet J, Smith KH, Bramlage P. Targeted therapies for treatment of nonsmall cell lung cancerrecent advances and future perspectives［J］. Int J Cancer, 2016, 138(11): 25492561. DOI: 10.1002/ijc.29915. ［3］ FrieseHamim M, Bladt F, Locatelli G, et al .The selective cMet inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant cMet activation in NSCLC models［J］. Am J Cancer Res, 2017, 7(4): 962972. ［4］ Jnne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitorresistant nonsmallcell lung cancer［J］. N Engl J Med, 2015, 372(18): 16891699. DOI: 10.1056/NEJMoa1411817. ［5］ Goss G, Tsai CM, Shepherd FA, et al. Osimertinib for pretreated EGFR Thr790Metpositive advanced nonsmallcell lung cancer (AURA2): a multicentre, openlabel, singlearm, phase 2 study［J］. Lancet Oncol, 2016, 17(12): 16431652. DOI: 10.1016/S14702045(16)305083. ［6］ Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinumpemetrexed in EGFR T790Mpositive lung cancer［J］. N Engl J Med, 2017, 376(7): 629640. DOI: 10.1056/NEJMoa1612674. ［7］ Park K, Lee JS, Han JY, et al. 130O: efficacy and safety of BI 1482694 (HM61713), an EGFR mutantspecific inhibitor, in T790Mpositive NSCLC at the recommended phase Ⅱ dose［J］. J Thorac Oncol, 2016, 11 Suppl 4: S113. DOI: 10.1016/S15560864(16)30243X. ［8］ Xu X, Mao L, Xu W, et al. AC0010, an irreversible EGFR inhibitor selectively targeting mutated EGFR and overcoming T790Minduced resistance in animal models and lung cancer patients［J］. Mol Cancer Ther, 2016, 15(11): 25862597. DOI: 10.1158/15357163.MCT160281. ［9］ Xu X. Parallel phase 1 clinical trials in the US and in China: accelerating the test of avitinib in lung cancer as a novel inhibitor selectively targeting mutated EGFR and overcoming T790Minduced resistance［J］. Chin J Cancer, 2015, 34(7): 285287. DOI: 10.1186/s4088001500293. ［10］ Thress KS, Paweletz CP, Felip E, et al. Acquired EGFR C797S mediates resistance to AZD9291 in advanced nonsmall cell lung cancer harboring EGFR T790M［J］. Nat Med, 2015, 21(6): 560562. DOI: 10.1038/nm.3854. ［11］ Jia Y, Yun CH, Park E, et al. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutantselective allosteric inhibitors［J］. Nature, 2016, 534(7605): 129132. DOI: 10.1038/nature17960. ［12］ Liu YT, Shi YK, Hao XZ, et al. Analysis of clinicopathological features of the echinoderm microtubuleassociated proteinlike4anaplastic lymphoma kinase fusion gene in Chinese patients with advanced nonsmallcell lung cancer［J］. Thorac Cancer, 2014, 5(3): 255260. DOI: 10.1111/17597714.12101. ［13］ Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALKpositive lung cancer［J］. N Engl J Med, 2013, 368(25): 23852394. DOI: 10.1056/NEJMoa1214886. ［14］ Solomon BJ, Mok T, Kim DW, et al. Firstline crizotinib versus chemotherapy in ALKpositive lung cancer［J］. N Engl J Med, 2014, 371(23): 21672177. DOI: 10.1056/NEJMoa1408440. ［15］ Sun HY, Ji FQ. A molecular dynamics investigation on the crizotinib resistance mechanism of C1156Y mutation in ALK［J］. Biochem Biophys Res Commun, 2012, 423(2): 319324. DOI: 10.1016/j.bbrc.2012.05.120. ［16］ Kim DW, Mehra R, Tan DS, et al. Activity and safety of ceritinib in patients with ALKrearranged nonsmallcell lung cancer (ASCEND1): updated results from the multicentre, openlabel, phase 1 trial［J］. Lancet Oncol, 2016, 17(4): 452463. DOI: 10.1016/S14702045(15)006142. ［17］ Crinò L, Ahn MJ, De Marinis F, et al. Multicenter phase Ⅱ study of wholebody and intracranial activity with ceritinib in patients with ALKrearranged nonsmallcell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND2［J］. J Clin Oncol, 2016, 34(24): 28662873. DOI: 10.1200/JCO.2015.65.5936. ［18］ Soria JC, Tan DSW, Chiari R, et al. Firstline ceritinib versus platinumbased chemotherapy in advanced ALKrearranged nonsmallcell lung cancer (ASCEND4): a randomised, openlabel, phase 3 study［J］. Lancet, 2017, 389(10072): 917929. DOI: 10.1016/S01406736(17)30123X. ［19］ Shaw AT, Gandhi L, Gadgeel S, et al. Alectinib in ALKpositive, crizotinibresistant, nonsmallcell lung cancer: a singlegroup, multicentre, phase 2 trial［J］. Lancet Oncol, 2016, 17(2): 234242. DOI: 10.1016/S14702045(15)00488X. ［20］ Ou SH, Ahn JS, De Petris L, et al. Alectinib in crizotinibrefractory ALKrearranged nonsmallcell lung cancer: a phase Ⅱ global study［J］. J Clin Oncol, 2016, 34(7): 661668. DOI: 10.1200/JCO.2015.63.9443. ［21］ Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALKpositive nonsmallcell lung cancer (JALEX): an openlabel, randomised phase 3 trial［J］. Lancet, 2017, 390(10089): 2939. DOI: 10.1016/S01406736(17)305652. ［22］ Perez CA, Velez M, Raez LE, et al. Overcoming the resistance to crizotinib in patients with nonsmall cell lung cancer harboring EML4/ALK translocation［J］. Lung Cancer, 2014, 84(2): 110115. DOI: 10.1016/j.lungcan.2014.02.001. ［23］ Gettinger SN, Bazhenova LA, Langer CJ, et al. Activity and safety of brigatinib in ALKrearranged nonsmallcell lung cancer and other malignancies: a singlearm, openlabel, phase 1/2 trial［J］. Lancet Oncol, 2016, 17(12): 16831696. DOI: 10.1016/S14702045(16)303928. ［24］ Kim DW, Tiseo M, Ahn MJ, et al. Brigatinib in patients with crizotinibrefractory anaplastic lymphoma kinasepositive nonsmallcell lung cancer: a randomized, multicenter phase Ⅱ trial［J］. J Clin Oncol, 2017, 35(22): 24902498. DOI: 10.1200/JCO.2016.71.5904. ［25］ Basit S, Ashraf Z, Lee K, et al. First macrocyclic 3rdgeneration ALK inhibitor for treatment of ALK/ROS1 cancer: clinical and designing strategy update of lorlatinib［J］. Eur J Med Chem, 2017, 134: 348356. DOI: 10.1016/j.ejmech.2017.04.032. ［26］ Zhou C, Wu YL, Chen G, et al. BEYOND: a randomized, doubleblind, placebocontrolled, multicenter, phase Ⅲ study of firstline carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous nonsmallcell lung cancer［J］. J Clin Oncol, 2015, 33(19): 21972204. DOI: 10.1200/JCO.2014.59.4424. ［27］ Ou SH, Tan J, Yen Y, et al. ROS1 as a ′druggable′ receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway［J］. Expert Rev Anticancer Ther, 2012, 12(4): 447456. DOI: 10.1586/ERA.12.17. ［28］ Bauer TM, Schuler M, Berardi R, et al. MINI01.03 phase (Ph) Ⅰ study of the safety and efficacy of the cMET inhibitor capmatinib (INC280) in patients with advanced cMET+ NSCLC topic: medical oncology［J］. J Thorac Oncol, 2016, 11(11S): S257S258. DOI: 10.1016/j.jtho.2016.09.018. ［29］ Borghaei H, PazAres L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous nonsmallcell lung cancer［J］. N Engl J Med, 2015, 373(17): 16271639. DOI: 10.1056/NEJMoa1507643. ［30］ Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamouscell nonsmallcell lung cancer［J］. N Engl J Med, 2015, 373(2): 123135. DOI: 10.1056/NEJMoa1504627. ［31］ RamosEsquivel A, van der Laat A, RojasVigott R, et al. AntiPD1/antiPDL1 immunotherapy versus docetaxel for previously treated advanced nonsmall cell lung cancer: a systematic review and metaanalysis of randomised clinical trials［J］. ESMO Open, 2017, 2(3): e000236. DOI: 10.1136/esmoopen2017000236. ［32］ Antonia S, Goldberg SB, Balmanoukian A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in nonsmall cell lung cancer: a multicentre, phase 1b study［J］. Lancet Oncol, 2016, 17(3): 299308. DOI: 10.1016/S14702045(15)005446. ［33］ Govindan R, Szczesna A, Ahn MJ, et al. Phase Ⅲ trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous nonsmallcell lung cancer［J］. J Clin Oncol, 2017, 35(30): 34493457. DOI: 10.1200/JCO.2016.71.7629.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[3]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[4]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[5]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[6]	顾芳萌, 徐晨阳, 雷大鹏. 人工智能辅助电子喉镜检查在喉癌及喉癌前病变诊治中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 303-307.
[7]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[8]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[9]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[10]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[11]	胡婷婷, 王越华. 电子鼻与线虫鼻——新型早期癌症筛查工具[J]. 国际肿瘤学杂志, 2024, 51(4): 223-226.
[12]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[13]	严爱婷, 王翠竹, 刘春桂, 鲁小敏. 卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[14]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[15]	钱晓涛, 石子宜, 胡格. Ⅲ~ⅣA期食管鳞状细胞癌根治性放化疗后行免疫检查点抑制剂维持治疗的真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(3): 151-156.